30 results
6-K
EX-99.1
PRFX
PainReform Ltd
26 Jun 24
PainReform Completes Enrollment in the Second Part
4:15pm
, non-opioid pain management solution to patients and healthcare providers. This innovative drug candidate leverages a patented, oil-based, extended … , including our Phase 2 trial results and the first part of our Phase 3 trial. With the opioid crisis continuing to affect millions worldwide
6-K
EX-99.3
PRFX
PainReform Ltd
15 May 24
Condensed Financial Statements
4:15pm
patients what we believe will be a far better alternative to systemic opioids, as we aim to tackle the global opioid epidemic.”
Financial Results
6-K
EX-99.1
PRFX
PainReform Ltd
2 Apr 24
PainReform Reaches 50% Enrollment in the Second Part of its Phase 3 Clinical
8:35am
opioids, which have contributed to the global opioid epidemic.”
About PainReform
PainReform is a clinical-stage specialty pharmaceutical company
6-K
EX-99.3
PRFX
PainReform Ltd
15 Nov 23
Condensed Financial Statements
4:09pm
the next step on this journey to help address the nationwide opioid epidemic.”
Financial Results for Nine Months Ended September 30, 2023
Research
6-K
EX-99.1
poca019s9 p0tz4
19 Jul 23
Current report (foreign)
9:08am
6-K
EX-99.3
f96 0g0f0
15 May 23
Condensed Financial Statements
4:51pm
6-K
EX-99.1
kds6aucwqvrkm5utk7x
1 May 23
PainReform Announces Positive Safety Data in First Part of Phase 3 Clinical Trial of PRF-110 in Patients Undergoing Bunionectomy Surgery
8:41am
6-K
EX-99.2
1vkoev x7l39ykd2t2e1
15 Aug 22
Current report (foreign)
6:16pm
6-K
EX-99.1
bi8nm44zd9 yn4
29 Jul 22
Investor Presentation July 2022
4:30pm
6-K
EX-99.1
g8wo 7bu0r
17 Mar 22
PainReform Provides Year-End Business Update; On track to Commence Phase 3 Trial of
8:31am
6-K
EX-99.3
iju8nn
13 May 21
PAINREFORM LTD. Condensed UNAUDITED FINANCIAL STATEMENTS
9:18am
20-F
8jeyuv58p1 9u
18 Mar 21
Annual report (foreign)
9:03am
6-K
EX-99.1
7ludyxitf3ag omvy
5 Jan 21
Investor Presentation January 2021
4:15pm
6-K
EX-99.1
ljmono4gm40sczdn
4 Jan 21
PainReform Announces Appointment of Lotus Clinical Research as CRO for Phase 3 Clinical Trial of PRF-110
4:16pm
424B3
caud34z
25 Nov 20
Prospectus supplement
11:12am
6-K
EX-99.1
913 x9pynpzdci4o
25 Nov 20
PainReform Appoints Senior Pharmaceutical Executive and Finance Veteran Ilan Hadar as Chief Executive Officer
10:08am
6-K
EX-99.1
mmf4jb4s chmwv
19 Oct 20
PainReform Highlights Surgical Advantages of PRF-110
1:37pm
424B4
cdhrebhx7k 5946jz
2 Sep 20
Prospectus supplement with pricing info
4:09pm